Danish drugmaker Novo Nordisk is preparing to introduce its blockbuster drug Ozempic (semaglutide) in India, a move expected to benefit millions of patients with Type 2 diabetes. The development was confirmed by the company’s India Head, Vikrant Shrotiya, in an exclusive conversation with India Today.
Ozempic, a once-weekly injectable, was originally approved for managing Type 2 diabetes but has since gained global attention for its effectiveness in weight management.
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.